Core Insights - Globus Medical reported revenue of $657.29 million for the quarter ended December 2024, reflecting a year-over-year increase of 6.6% and surpassing the Zacks Consensus Estimate by 2.02% [1] - The company's EPS for the quarter was $0.84, which is an increase from $0.60 in the same quarter last year, resulting in an EPS surprise of 10.53% over the consensus estimate of $0.76 [1] Revenue Breakdown - International revenues reached $135.40 million, exceeding the average analyst estimate of $133.48 million, marking a 7.7% increase year-over-year [4] - U.S. revenues totaled $521.89 million, surpassing the average estimate of $506.62 million, with a year-over-year growth of 6.3% [4] Product Category Performance - Net sales from Enabling Technologies were reported at $46.95 million, significantly higher than the estimated $38.17 million, representing a substantial year-over-year increase of 43.5% [4] - Net sales from Musculoskeletal Solutions amounted to $610.34 million, exceeding the average estimate of $597.20 million, with a year-over-year growth of 4.5% [4] Stock Performance - Over the past month, shares of Globus Medical have declined by 9.9%, contrasting with a 2.6% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Globus Medical reported quarterly earnings of $0.84 per share, exceeding the Zacks Consensus Estimate of $0.76 per share, and showing an increase from $0.60 per share a year ago, resulting in an earnings surprise of 10.53% [1] - The company achieved revenues of $657.29 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 2.02% and up from $616.53 million year-over-year [2] - The stock has underperformed the market with a gain of about 1.7% since the beginning of the year, compared to the S&P 500's gain of 4.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.79 on revenues of $647.24 million, and for the current fiscal year, it is $3.47 on revenues of $2.67 billion [7] - The estimate revisions trend for Globus Medical is mixed, leading to a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which Globus Medical belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, OrthoPediatrics, is expected to report a quarterly loss of $0.22 per share, with revenues projected at $52.7 million, reflecting a 40.1% increase year-over-year [9][10]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ Title of each class Trading Symbol(s) Name of exchange on which registered Class A Common Stock, par value $.001 per share GMED New York Stock E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2025 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403-5214 (Address of princ ...

AUDUBON, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2024. Fourth Quarter 2024: Worldwide net sales were $657.3 million, an increase of 6.6% on an as-reported basis and an increase of 6.9% on a constant currency basisGAAP net income for the quarter was $26.5 millionGAAP diluted earnings per share (“EPS”) was $0.19 and non-GAAP diluted EPS was $0 ...

AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the ...

AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by th ...

Core Viewpoint - Globus Medical, Inc. will announce its financial results for Q4 and the full year ended December 31, 2024, on February 20, 2025, after market close [1] Group 1: Financial Results Announcement - The financial results will be available on the Globus Medical website [1] - A teleconference will be held to discuss the performance with the investment community at 4:30 p.m. Eastern Time on the same day [2] - Participants can access the conference call live via webcast on the Investors page of the Globus Medical website [2] Group 2: Participation Details - Telephone participants must register in advance to receive a confirmation email with details on how to join the call [3] - An audio archive of the call will be available on the Investors page after the event [3] Group 3: Company Overview - Globus Medical, Inc. is based in Audubon, Pennsylvania, and is a leading global musculoskeletal company focused on addressing unmet clinical needs [4] - The company emphasizes innovation, education, and clinical support across various areas including spine, orthopedic trauma, joint reconstruction, and enabling technologies [4]

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Globus Medical (GMED) . This company, which is in the Zacks Medical - Instruments industry, shows potential for another earnings beat.This medical device company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 18.99%.F ...

Core Viewpoint - Globus Medical is experiencing growth in demand for its Musculoskeletal Solutions products, but faces challenges from a difficult macroeconomic environment [1] Factors Driving GMED's Shares - The company is gaining market share in musculoskeletal solutions, driven by strong performance in implantable devices, biologics, accessories, and surgical instruments [2] - Notable growth is observed in expandables, biologics, minimally invasive screws, 3D printed implants, and cervical offerings [2] - In Q3, pro forma musculoskeletal revenues increased by 5.4%, marking the fourth consecutive quarter of growth, primarily from U.S. and international spine businesses [3] - Enabling Technologies revenues grew by 39% year over year, fueled by increased sales in the U.S. market [3] Product Launches - Four new products were launched in Q3, including the Excelsius Navigation Hub, which offers unique imaging workflows [4] - The Actify 3D Total Knee system was introduced, enhancing operative efficiency and anatomical fit [5] - The CAPTIVATE SOLA headless compression screw system was launched for various orthopedic applications [5] Merger and Synergies - The merger with NuVasive has created a global musculoskeletal company focused on innovation and addressing clinical needs [6] - The combined entity expects to generate $170 million in synergies over three years, with 40% realized in the first year [7] Business Performance - The combined trauma and NSO business reported a 99% growth in Q3, driven by strong market penetration [8] - Over the past three months, GMED shares increased by 24.3%, outperforming the industry average of 0.2% [9] Challenges Faced - The company is affected by negative global economic trends, including interest rate fluctuations and inflation, impacting operations and financial performance [10] - A significant 99.8% increase in the cost of goods sold was reported in Q3, alongside a 54.1% rise in SG&A expenses [11] - The musculoskeletal devices market is highly competitive, necessitating continuous product innovation to maintain market share [12]